Background: persistent pulmonary hypertension of the newborn (PPHN) is a serious medical emergency in the neonatal period which occurs because of the failure of the transition of the fetal circulation into the normal circulation. The condition is characterized by persistently elevated pulmonary vascular pressures and despite numerous modalities of treatment available, the condition carries with it a high rate of mortality and morbidity. Objective: To evaluate the response to inhaled versus intravenous magnesium sulfate (MgSO4) in the treatment of pulmonary hypertension in neonates. Methodology: This is an observational prospective study done in Sohag university hospital in the neonatal intensive care unit during the period from January 2016 to December 2017 on 50 neonates who were diagnosed to have PPHN by echocardiography. In this study, we compared the effect of intravenous versus the inhalational MgSO4 on reducing the PHN and SILDENAFIL was used as an adjuvant treatment. Results: there was a statistically significant difference between the three studied groups as regard: age (P value 0.034), sex (P-value 0.001), the degree of respiratory distress (P-value 0.01), the pulmonary artery pressure before treatment (P-value <0.001), side effects of treatment (P-value 0.012), duration of treatment (P-value <0.001) and the SpO2 after treatment (P-value 0.005). Also there was a great difference in SpO2 in the right hand before and after treatment; P value was <0.001 in group A and 0.002 in both group B and C. Pulmonary artery pressure as well differs greatly before and after treatment in the three groups; P value was <0.001 in group A and 0.002 in both group B and C. Conclusion: Based on this study we don't recommend the use of nebulized MgSO4 alone as a treatment of PPHN in neonates (as no improvement occurred in patients used it alone).
Introduction
Pulmonary hypertension of the newborn occurs in 1.9 per 1000 live births and affected infants are hypoxaemic because of right-to-left shunts through the ductus arteriosus and foramen ovale. Pulmonary hypertension of the new-born may be primary, or secondary to a variety of conditions [1] .
The primary form of the disease presents soon after birth with hypoxemia in a baby with normal lungs clinically and radiologically. Usually, it is associated with high-risk pregnancies as diabetes mellitus, hypertension, and maternal indomethacin intake. Secondary causes include congenital heart malformations (most commonly associated with obstruction to pulmonary venous drainage), high output cardiac failure from large arteriovenous malformations and persistent pulmonary hypertension of the newborn (PPHN); of these, the most common cause is PPHN [2] . PPHN develops when pulmonary vascular resistance (PVR) remains elevated after birth, resulting in the right-to-left shunting of blood through fetal circulatory pathways. The PVR may remain elevated due to pulmonary hypoplasia, like that seen with a congenital diaphragmatic hernia; maldevelopment of the pulmonary arteries, seen in meconium aspiration syndrome; and maladaptation of the pulmonary vascular bed as occurs with perinatal asphyxia. Infants with PPHN have cyanosis, tachypnea, acidaemia, normal pulmonary parenchymal markings on the chest radiograph, and anatomically normal hearts [3] . Doctors have been using magnesium sulfate (MgSO4) for many years in the treatment of toxemia of pregnancy. It is a natural calcium antagonist. It acts on the metabolism of prostaglandin, suppresses the release of catecholamines, reduces the responsiveness of smooth muscles to vasopressors. Also, MgSO4 at high concentration is a potent vasodilator and can prevent and reduce pulmonary hypertension caused by hypoxia, sedative, muscle relaxant and has an antithrombotic action on the brain and kidney [4, 5] . MgSO4 is a safe and cheaper alternative for first-line treatment in moderate PHN and was chosen to be an alternative therapy for PHN when other conventional treatments fail, contraindicated or not available. Magnesium sulfate can dilate the constricted muscles in the pulmonary arteries. However, its action is not specific and when given via an intravenous infusion, it will act on other muscles in the body including other arteries. This means that even if it was found to be effective in pulmonary hypertension, unwanted actions in other parts of the body might be a problem [4] . However, inhaled magnesium sulfate has not been studied yet for the treatment of pulmonary hypertension. Sildenafil is a phosphodiesterase type5 inhibitor that reduces pulmonary vascular resistance selectively. It also is great in the treatment of infants with PPHN. It is available now in both oral and intravenous forms; however, there is an increased risk of systemic vasodilation with the I.V rout. 
Aim of the work

Methods of the study:
Patients included in the study were subjected to the following (diagnostic criteria of pulmonary hypertension): inhalational magnesium sulfate (100_ 300 mg + 4 ml sterile water) according to the severity of respiratory distress for 3 times daily with daily Echo follow up but there was no improvement in the general condition or pulmonary pressure, so oral sildenafil was added after 24 hours in a dose of 1 mg\kg\day in four divided doses (via the nasogastric tube) with daily Echo follow up until pulmonary artery pressure reached 30 mmHg. And as a result, we decided to change our protocol of administration and added oral sildenafil from the start to patients who receive inhalational MgSO4 to save the lives of our neonates.
Group C: (12 patients)
Received inhalational MgSO4 (100-300 mg + 4 ml sterile water) according to the severity of respiratory distress for 3 times daily together with oral sildenafil in a dose of 1 mg\kg\day in four divided doses (via the nasogastric tube) with daily Echo follow up until pulmonary artery pressure reached 30 mmHg.
Statistical analysis: Data were analyzed using IBM SPSS Statistics for Windows version 23.0.
Quantitative data were expressed as mean ± standard deviation, median, and range. Qualitative data were expressed as number and percentage. The data were tested for normality using the Shapiro-Wilk test. The nonparametric Wilcoxon Signed Ranks test and Kruskal-Wallis test were used for data that wasn't normally distributed. One-Way ANOVA test was used for normally distributed data. Chi-square (χ2) test and Fisher's Exact Test were used for comparison regarding qualitative variables as appropriate. A 5% level was chosen as a level of significance in all statistical tests used in the study. 
Results:
P-value was calculated by Chi-square test * P-value was calculated by Kruskal Wallis Test P-value < 0.05 is statistically significant
The mean age in each studied group was as follows: in group A: 2.5 days, in group B 4.33 days and group C 1.83 days. Sex distribution was 50% male and 50% female in group A, 16.7% male, and 83.3 % female in group B and 91.7% male and 8.3% female in group C with statistically significant P value between the studied groups as regard age and sex. 
a comparison between group A and group B. P2 a comparison between group A and group C. P3 a comparison between group B and group C. P values were calculated by Fisher's Exact Test
As regards the side effects of treatment, hypotension was the only side effect and occurs in 30.8% of group A with no reported cases in both group B and group C. P-value shows a statistically significant difference between the study groups. When we talk about the duration of treatment, it appears that there's a statistically significant difference between the studied groups. In group A it was (2_7) days, while in group B it was (4_7) days and in group C it was (5_10) days. SpO2 after the treatment also differs significantly in the studied groups, in group A mean oxygen saturation was 94.58 while in group B was 92.5 and in the group, C was 91.75 PAP in the three studied groups after treatment was equal to 30 mmHg as it was the cut-off point for termination of treatment, and therefore there was no statistically significant difference between them. ABG also was normal in 100% of cases after treatment.
Table(6): Comparison between the three studied groups regarding duration & outcome of treatment and supportive treatment. P-value compared the three groups. p1 a comparison between group A and group B. P2 a comparison between group A and group C P3 a comparison between group B and group C
As regards the mortality rate in the studied groups, it was 7.7% of group A and 16.7% in both groups B and C. Other morbidities which included NEC and \ or sepsis, occurred in 30.7% of group A, 33.3% of group B and 66.7% of group C. Patients received supportive treatment in the form of CPAP were 46.2% of group A, 50% of group B and 75% of group C, while who received supportive treatment in the form of Oxygen were 58.3% of group A, 50% of group B and 25%of group C. There was a statistically insignificant difference between the studied groups as regards ABG, mortality rate, other morbidities, and supportive treatment.
Table (7): Comparison of SpO2 (RT hand) before the treatment and post-treatment SpO2 (%) in the study groups
P-value was calculated by Wilcoxon Signed Ranks test *Statistically significant
When we compared SpO2 in the right hand before and after treatment there was a statistically significant difference in all studied groups; in group A the mean SpO2 before treatment was 79. 15 
This table shows the difference in PAP before and after treatment with an obvious statistically significant difference between them. In the group, A mean pulmonary pressure before treatment was 69.81mmHg while after treatment was 30 mmHg. In the group, B mean pulmonary pressure before treatment was 57.08mmHg while after treatment was 30 mmHg.
In the group, C mean pulmonary pressure before treatment was 78.17 mmHg while after treatment was 30 mmHg.
Discussion
Davidson et al. [6] in their study showed that early I-NO as the sole adjunct to conventional management produced acute and sustained improvement in oxygenation for 24 hours without short-term side effects [5 and 20 ppm doses], and the suggestion that ECMO use may be reduced. In two large randomized studies, so reduced the need for ECMO support by about 40%. However, it did not reduce mortality, the duration of hospitalization, or the risk of neurodevelopmental impairment [7] . Currently, the initial recommended dose of iNO is 20 ppm. Higher doses have the same efficacy and are associated with an increased risk of methemoglobinemia and the formation of nitrogen dioxide [8]. However, unfortunately, so is not available in our country and we have to use other available treatment modalities such as MgSO4 and sildenafil for treating patients with PPHN. In this study, we tried to evaluate the response to nebulized magnesium sulfate as a new modality of treatment in PPHN. Magnesium sulfate enhances vasodilatation by promoting the entry of calcium ions into the smooth muscle cells. MgSO4 was listed as a safe and effective pulmonary vasodilator according to Chandran et al. [9] . MgSO4 can be used as a first-line pulmonary vasodilator because it has a low cost and high efficacy. IV MgSO4 can be used and monitored easily during treatment. However, systemic hypertension occurs more with IV MgSO 4 [10]. In patients with acute asthma, isotonic magnesium sulfate, as a vehicle for nebulized salbutamol, increased the peak flow response to treatment in comparison with salbutamol plus normal saline according to Nannini et al. [11] . However the use of nebulized MgSO4 as a pulmonary vasodilator hasn't been tried yet worldwide, and we concluded to this result after great effort in search in many books, researches, and articles that were published internationally. So we conducted this study based on two facts, the first was the approved efficacy of parenteral MgSO4 as a bronchodilator and vasodilator also as mentioned above, and the second was the documented use of nebulized MgSO4 as a bronchodilator in management of mild to severe asthma and its acute exacerbations. Also, nebulized MgSO4 would have the advantage of avoiding systemic hypotension that occurs with intravenous MgSO4. The three studied groups were compared to each other as regard age, sex, anthropometric measures, maternal history, and neonatal examination before and after treatment, laboratory investigations, chest X-ray, echo before and after treatment, side effects of treatment, duration and outcome of treatment. As regard age and sex, P-value was 0.034 and 0.001 respectively between the three studied groups which are statistically significant. There was also a statistically significant difference between the three studied groups concerning the degree of respiratory distress [P value 0.01], the pulmonary artery pressure before treatment [P value <0.001], side effects of treatment [P value 0.012], duration of treatment [P value <0.001] and the SpO2 after treatment [P value 0.005]. In our study the number of neonates in group A was 26 with male: female ratio 1:1 and the number in group B was 12 with male: female ratio 1:5 and 12 patients in group C and male: female ratio was 11:1 while the result of Uslu et al. [12] was somewhat different, it included 34 patients in intravenous MgSO4 group with male: female ratio 1.44:1 and 31 patients in oral sildenafil group with male: female ratio 1.1:1 but different to the result of Dhariwal et al. [13] whose male: female ratio was 5:1
The mean age in group A was 2.5 days while in group B was 4.3 days and in the group, C was 1.8 days which was very close to the result of Uslu et al. [12] where the median age was 2 days in each group but quite far from the results of Steinhorn et al. [14] where the mean age was 34 hours. As regard maternal DM in our study 8% of neonates were infants of diabetic mothers but it was 5% in the study of Razzaq et al. [15] maternal hypertension and\or PET was positive in 6% of cases while it was positive in only 3.8% of cases in the study of Razzaq et al. [15] . Also, the study of Delaney et al. [16] showed that maternal DM and PET are among the factors associated with an increased risk for PPHN. Maternal PROM didn't occur at all in our study just like the results of Hernández-Díaz [17] . In our study, the mean neonatal weight was 2.9 kg in both group A & C and 2.7 in group B that's near the neonatal weight in the study of Uslu et al. [12] that was 3.2 kg and the study of Nakwan et al. [18] that was 3.4 kg The mean height in our study was 49.7 cm and the mean head circumference was 34.6 cm in all groups that were very close to the mean height and head circumference in the study of Uslu et al. [12] which were 49.9 cm and 35 cm respectively and 49.8 cm and 34.8 cm in the study of Nakwan N. et al.. [18] . Respiratory distress was found in 100% of cases in our study that's the same as in Uslu et al. study. [12] and near the result of Tissot et al. [19] that was 86% Down syndrome was found in only 2% of neonates in our study and also hydrocephalus that's quite near to the results of Cua et al. [20] that showed that 1.2% of cases had down syndrome but none had hydrocephalus. In our study, the mean SpO2 was 79.15% in group A and 83.4% in group B and 79.9% in group C which was higher than the results of Uslu et al. [12] in which SpO2 was 64.3% in the MgSO4 group and 66% in the sildenafil group. Heart sounds were normal in 80% of cases in this study while only 20% had single loud S2 and also 38% of cases had the murmur of tricuspid regurgitation. This result is different from the result of Bakheet et al. [21] in which 88% of cases had single loud S2. As regard laboratory investigations in our study 90% of cases had normal CBC, 92% had normal blood glucose levels and 90% had normal serum electrolytes which is very close to the results of Hageman et al. [22] in which CBC was normal in 93% of cases, and normal blood glucose and serum electrolytes in the vast majority of cases and Razzaq et al. [15] study that had 96.9% of cases with normal CBC. The ABG in our study showed only 6% of cases had compensated metabolic acidosis, 40% had uncompensated metabolic acidosis and 100% of cases had profound hypoxemia which completely agrees with results of Uslu et al. [12] and Razzaq et al. [15] that showed that 100% of cases had profound hypoxemia. Chest X-ray findings in our study were normal in 64% of cases that is agree with the study of Sharma et al. [10] that show that lung fields are clear or minimally opacified on X-ray but in Bakheet et al. study [21] show 38% had cardiomegaly. The PAP in our study had a mean of 69.8 mmHg in group A, 57.08 mmHg in group B and 78.17 mmHg in group C which is much higher than that of Uslu et al. [12] that was 45.6 mmHg in the MgSO4 group and 46.2 mmHg in the sildenafil group. Also, the median of PAP in our study which was 70 mmHg in all groups is much higher than the median of PAP in the study of Milman et al. [23] that was 36 mmHg. Time taken to achieve adequate response in our study was 2 -7 days in group A, 4 -7 days in group B and 5 -10 days in group C and this result is somewhat near to the result of Uslu, et al. [12] that was 1 -12 days in MgSO4 group and 1 -11 days in the sildenafil group. The mean duration of treatment was 3.1 days in the study of Tolsa et al. [24] which is nearly the same as our result which was 3.4 days. The cut-off point of PAP in this study was 30 mmHg which was achieved in all patients but in different durations and supportive measures either CPAP or inhaled oxygen, while the PAP cut off point in Uslu et al. [12] study was 20 mmHg. Mortality rate in this study was 7.7% in group A and 16.7% in both group B&C while it was 5.9% in MgSO4 group and 3.2% in the sildenafil group in Uslu et al. [12] study, and was 11% in the study of Michele et al. [25] which is probably due to the larger number of cases in their studies. Associated morbidities in our study included sepsis which occurred in 30% of cases in all groups while sepsis occurred in 29.1% of cases in the study of Razzaq et al. [15] that's approximately the same. 54% of our cases used CPAP as a supportive treatment and 46% used Oxygen only while in the study of Razzaq et al. [15] 64.5% of cases used CPAP which is very close to our results, 15.1% used Oxygen and the rest 20.4% used intermittent mandatory ventilation which hasn't been used in our study. Oral sildenafil was used in group B&C as an associated treatment because of its proved efficacy as it is a phosphodiesterase type5 inhibitor which reduces the pulmonary vascular resistance selectively as proved by Hernando Baquero et al. [26] .in the present study s was added to patients who didn't respond to inhalational MgSO4 for 24 hours and their general condition became worse and then we decided to use it from the start as an adjuvant treatment in patients with higher pulmonary pressure to save their lives. So this study was the first trial to evaluate the response to nebulized magnesium sulfate as a new modality of treatment in PPHN. We just opened a window for further researches to be held on this topic.
Limitations of this study included:
 The small number of patients.  Calculation of the dose of nebulized MgSO4 was based on our trials but no documented dose was used as this route of administration hasn't been tried yet before, so dose adjustment might have some fallacies.  Nebulizers available in our study are of the pneumatic type which is much less efficient than ultrasonic nebulizers.
Recommendation:
So, based on this study we don't recommend the use of nebulized MgSO4 alone as a treatment of PPHN in neonates (as no improvement occurred in patients used it alone) and use other treatment modalities available in our country until other researches or studies can prove the reverse of our results.
